Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors

Basit Öğe Kaydı
dc.contributor.authorAy Y.
dc.contributor.authorBalkan C.
dc.contributor.authorKarapinar D.Y.
dc.contributor.authorAkin M.
dc.contributor.authorBilenoglu B.
dc.contributor.authorKavakli K.
dc.date.accessioned2019-10-27T08:23:33Z
dc.date.available2019-10-27T08:23:33Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Monitoring bypassing agent therapy and observing concordance with clinical hemostasis is crucial in vital hemorrhages and major surgeries in patients with hemophilia having inhibitor. Objective: We aimed to investigate the value of the thrombin generation assay (TGA) and thromboelastography (TEG) for monitoring hemostasis in patients with hemophilia having inhibitor, during supplementation therapy with bypassing agents. Patients and Methods: The study group consisted of 7 patients with hemophilia having factor VIII inhibitor. All patients were male. The median age of the participants was 10 years. Age range was 6 to 32 years. The median inhibitor level was 10 Bethesda units (BU), with a range of 5 to 32 BU. A total of 17 bleeding episodes were evaluated. Both TEG and TGA tests were assessed in addition to clinical responses. Assessments were made prior to bypass agent therapy such as recombinant factor VIIa (rFVIIa) or activated prothrombin complex concentrate (aPCC) for bleeding episodes, during the first hour and 24 hours after either intervention in patients. Results: No relation between clinical response and TGA or TEG parameters was found in patients. There was no difference between clinical responses after rFVIIa and aPCC treatments. However, after aPCC treatment, endogenous thrombin potential and peak thrombin levels and also TEG R, K, and alpha angle degrees were significantly higher. Conclusions: In conclusion, we found that the clinical effectiveness of bypass therapy in hemophilia cannot be assessed by TGA and TEG. © 2012 The Author(s).en_US
dc.identifier.doi10.1177/1076029612438611en_US
dc.identifier.endpage394en_US
dc.identifier.issn1076-0296
dc.identifier.issue4en_US
dc.identifier.pmid22395575en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage389en_US
dc.identifier.urihttps://doi.org/10.1177/1076029612438611
dc.identifier.urihttps://hdl.handle.net/11454/26445
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofClinical and Applied Thrombosis/Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbypassing agentsen_US
dc.subjecthemophiliaen_US
dc.subjectinhibitoren_US
dc.subjectthrombin generation assayen_US
dc.subjectthromboelastographyen_US
dc.titleFeasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu